Tiara: A Novel Catheter-Based Mitral Valve Bioprosthesis Initial Experiments and Short-Term Pre-Clinical Results by Banai, Shmuel et al.
Journal of the American College of Cardiology Vol. 60, No. 15, 2012
© 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc.CORRESPONDENCE
Research
Correspondence Tiara: A Novel Catheter-Based Mitral Valve BioprosthesisInitial Experiments and Short-Term Pre-Clinical ResultsTo the Editor: Novel percutaneous transcatheter technologies are
emerging as alternatives to surgery for high-risk patients (1).
Transcatheter mitral valve (MV) implantation has the potential to
become the preferred intervention to treat severe mitral regurgita-
tion in these patients, because theoretically it can reduce mitral
regurgitation to an extent similar to that of surgery while preserv-
ing the mitral apparatus. However, many challenges need to be
addressed in the design and development of a device to be
deployed across an asymmetric and multiplanar MV annulus (2).
Transcatheter MV implants should restore unidirectional flow,
spare chordal structures, and leave adjacent myocardium intact,
while minimizing the risks associated with the procedure, allowing
high-risk patients who are not candidates for surgery to receive
definitive treatment. Herein we report our preclinical, short-term
safety and feasibility experience with the Tiara valve (Neovasc,
Inc., Richmond, British Columbia, Canada), a catheter-based,
self-expanding mitral bioprosthesis.
The Tiara comprises a self-expanding frame and biological
tissue leaflets fixed within this frame. Its atrial portion is designed
specifically to fit the saddle-shaped mitral annulus. The Tiara
orifice is D-shaped to match the natural shape of the mitral orifice,
and when implanted, the flat side of the D is positioned anteriorly
to prevent impingement of the left ventricular outflow tract
(LVOT). The ventricular portion of the device comprises a
covered so-called skirt structure that prevents paravalvular leak as
well as 3 anchoring structures. The 2 anterior anchoring structures
are designed to capture the fibrous trigones on both sides of the
anterior mitral leaflet, whereas the posterior anchoring structure
projects behind the posterior mitral leaflet, creating a 3-point
anchor on the ventricular side that works in conjunction with the
atrial flange to secure the Tiara within the mitral annulus. This
securement prevents retrograde dislodgement during systole. The
prosthetic valve leaflets are specially designed in a D configuration
to match the valve frame orifice.
Tiara implantation is performed by a multidisciplinary team
including 2 interventional cardiologists, a cardiac surgeon, and an
echocardiographer. Before implantation, transesophageal echo
(TEE) measurements of the left atrium, and mitral annulus
dimensions are performed. Through a subxiphoid incision of less
than 5 cm, an apical puncture is performed and a J-tipped
0.035-inch guidewire is advanced across the mitral apparatus into
the left atrium. The Tiara valve loaded within a 30-F deployment
catheter is advanced over the guidewire and is positioned in the left
atrium. On angiographic and TEE confirmation of proper posi-
tioning of the Tiara delivery system, the guidewire is removed. A
single thumbwheel retracts a sheath covering the device and
controls the entire deployment process. Tiara deployment follows
the sequence of first deploying and orienting the atrial flange
portion. This is accomplished readily using fluoroscopy to visualize
the device and radiopaque markers located at specific points on thestructure, so that the flat aspect of the D-shaped prosthesis is
aligned with the LVOT and the aorta. The valve then is pulled
downward to seat the atrial flange firmly on the floor of the atrium,
and the 3 ventricular anchor structures then are deployed to
capture the fibrous trigones and posterior mitral leaflet. After these
3 anchors are deployed fully, the ventricular skirt and valve leaflets
are released from the catheter, allowing the device to begin
functioning in place of the native valve. In all stages of valve
deployment until the final step of ventricular deployment, it is
possible to recapture the partially deployed valve into the delivery
catheter, reposition it, and restart the implantation process. Tiara
implantation does not require rapid pacing and does not cause any
hemodynamic instability.
Immediately after deployment, the delivery system is removed
and hemostasis is secured with previously placed pledgeted apical
sutures. Mitral and aortic valve function, presence of an LVOT
gradient, valvular or paravalvular regurgitation, aortic valve gradi-
ent, and patency of the left circumflex coronary artery are ruled out
by TEE, cardiac catheterization, or both.
All animals with successful implantation were monitored he-
modynamically for a minimum of 90 min, and after an additional
echocardiographic evaluation of the MV, all but 7 animals were
killed. The surviving animals were extubated and allowed to
recover from anesthesia and monitored clinically for 4 to 96 h (per
protocol) before they were killed.
Tiara valves were implanted successfully in 29 (81%) of 36
domestic swine with fluoroscopic and 3-dimensional TEE guid-
ance (Fig. 1). Follow-up varied from 90 min to 96 h. Total
procedure time ranged from 17 to 26 min, and the prosthesis
deployment time ranged from 5 to 13 min after the apical access.
In the 29 successful implantations, TEE demonstrated excellent
function and alignment of the Tiara, with no LVOT obstruction,
no pericardial effusion, no encroachment on the aortic valve, and
no transvalvular gradients. Significant paravalvular leak was seen
only in cases of either MV annulus–prosthesis mismatch or failed
implantation. Macroscopic evaluation of the explanted hearts
demonstrated stable and secure positioning of the valves in all
planes of the mitral apparatus. There was a steady increase in the
rate of successful implantation as the series progressed, with the
final 12 animals in the series all undergoing successful and
uneventful implantations. All 29 animals that underwent successful
Tiara implantation remained hemodynamically stable throughout
the implantation procedure.
Our initial preclinical experience with the Tiara transcatheter
self-expanding mitral bioprosthetic valve is encouraging. We
demonstrated that the implantation of the Tiara valve is feasible,
relatively straightforward, and results in a stable and well-
functioning MV bioprosthesis. Successful completion of long-term
preclinical trials of the Tiara valve will lead the way to human
clinical trials.
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Cardiac Arrest in a
Long-Distance Ski Race
(Vasaloppet) in Sweden
To the Editor: Physical training is generally regarded as beneficial
for health. Heavy endurance exercises might, however, induce
latent ischemic heart disease and acute cardiac arrhythmias. Kim et
al. (1) recently reported on the incidence of cardiac arrest (CA)
during long-distance running. Exercise in combination with a cold
climate may be especially detrimental and trigger acute cardiac
events (2). The incidence of CA during strenuous competitive
exercise is uncertain. We aimed to investigate the absolute and
relative risk for CA during long distance ski racing. Thus, we
ote the D-shaped prosthetic valve. (A) Diastole; (B) systole; (C) 3D TEE ventricu-
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